IQ-AI Limited

19 July 2023

19 July 2023


("IQ-AI" or the "Company")

Imaging Biometrics Installs IB Nimble(TM) For MCW Bone Mets Treatment

Imaging Biometrics, LLC (IB), a wholly-owned subsidiary of IQ-AI Ltd (LSE: IQAI, OTCQB: IQAIF), today announced that its handheld application, IB Nimble, has been adopted by Orthopedic Department of the Medical College of Wisconsin for use in their treatment of bone metastases. The handheld app provides real-time collaboration amongst multi-disciplinary teams securely and asynchronously.

Designed initially by Dr. Joseph Bovi, MD, Professor of Radiation Oncology and Neurosurgery at MCW, for brain metastases, IB Nimble's base functionality has been enhanced to accommodate any disease or pathology that requires multi-disciplinary input. The clinical benefit of providing optimized treatments faster to patients with brain metastases is now being afforded to patients with bone mets.

"This marks the first installation for use in diseases sites other than brain metastases and demonstrates that IB Nimble is ready for widespread deployment," said Josh McComack, IB's Director of Software Engineering.


The Directors of the Company accept responsibility for the contents of this announcement.

For further information, please contact:

 IQ-AI Ltd 
  Trevor Brown/Vinod Kaushal/Brett Skelly/Michael Schmainda 
  Tel: 020 7469 0930 
 Peterhouse Capital Limited (Financial Adviser and Broker) 
  Lucy Williams/Heena Karani 
  Tel: 020 7220 9797 

About Imaging Biometrics(R) LLC: IB is a wholly-owned subsidiary of IQ-AI Limited, (LON: IQAI) (OTCQB: IQAIF), and focuses on delivering quantitative imaging platforms and therapeutics that transform how clinicians diagnose and treat patients more efficiently and effectively. For more information about Imaging Biometrics, visit the

company's website at www.imagingbiometrics.com .   Follow IB on Twitter, @IQAI_IB. 

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.



(END) Dow Jones Newswires

July 19, 2023 02:00 ET (06:00 GMT)

Iq-ai (LSE:IQAI)
Historical Stock Chart
From Oct 2023 to Nov 2023 Click Here for more Iq-ai Charts.
Iq-ai (LSE:IQAI)
Historical Stock Chart
From Nov 2022 to Nov 2023 Click Here for more Iq-ai Charts.